AMP 514

Drug Profile

AMP 514

Alternative Names: AMP-514; MEDI-0680

Latest Information Update: 09 Dec 2016

Price : $50

At a glance

  • Originator Amplimmune
  • Developer Amplimmune; MedImmune
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action PDCD 1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II B cell lymphoma
  • Phase I Solid tumours

Most Recent Events

  • 07 Oct 2016 Efficacy, adverse event and immunogenicity data from a phase I trial in Cancer presented at the 41st European Society for Medical Oncology Congress (ESMO-2016)
  • 07 Oct 2016 Safety, efficacy, pharmacokinetics and pharmacodynamics results from the phase I trial presented at the 41st European Society for Medical Oncology Congress (ESMO-2016)
  • 15 May 2016 MedImmune completes a phase I/II trial in B-cell lymphoma (Combination therapy, Second-line therapy or greater) in USA (NCT02271945)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top